RxDoctor Payments Data

Hector Malave, MD

Cardiovascular Disease · Atlanta, GANPI 1083620504

Payments from drug & device makers

$12,850in general payments, 2019–2025

Across 668 payments — averaging $19.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Amgen$1K
  • Boehringer Ingelheim$1K
  • Novartis$965
  • Johnson & Johnson$868
  • Merck$794
  • plus $6K from 35 others

What the payments were for

  • Speaking & faculty fees$200%
  • Food & beverage$12,786100%
  • Education$430%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,850 in reported general payments places this provider in the 80th percentile of 640 cardiovascular disease providers in Georgia.

See all cardiovascular disease providers in Georgia

Medicare billing

Part B allowed, 2024
$483,725
Medicare patients
835
Services billed
4,289

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban548$639,450
XareltoRivaroxaban303$372,593
Repatha SureclickEvolocumab272$327,450
JardianceEmpagliflozin248$295,122
EntrestoSacubitril/Valsartan194$242,758
FarxigaDapagliflozin Propanediol152$169,862
Praluent PenAlirocumab85$68,011
BrilintaTicagrelor80$66,044
MultaqDronedarone Hcl29$48,563
VascepaIcosapent Ethyl70$48,362
VerquvoVericiguat30$41,034
OzempicSemaglutide22$35,456
NexlizetBempedoic Acid/Ezetimibe34$32,204
NexletolBempedoic Acid28$23,711
Ezetimibe471$12,902

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$471$639,450548 claims
Johnson & JohnsonXarelto$868$372,593303 claims
Boehringer IngelheimJardiance$1,168$295,122248 claims
NovartisEntresto$965$242,758194 claims
AstraZenecaFarxiga, Brilinta$1,472$235,906232 claims
Esperion Therapeutics, Inc.Nexlizet, Nexletol$483$55,91562 claims
Sanofi-aventis U.S. LLCMultaq$777$48,56329 claims
MerckVerquvo$794$41,03430 claims
Novo NordiskOzempic$482$35,45622 claims
Kowa Pharmaceuticals America, Inc.Bystolic, Livalo$384$8,07123 claims
Arbor Pharmaceuticals, Inc.Edarbi$51$7,30111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 640 cardiovascular disease providers in Georgia.

Other cardiovascular disease in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →